First 2 Quarters of Fiscal 2021 Supplementary Materials

## Table of Contents

## Consolidated Basis

Statements of Income (First 2 Quarters Results) ..... $1 P$
Statements of Income (Full-year plan) ..... $2 P$
Sales by Product Grouping (First 2 Quarters Results and full-year plan) ..... $3 P$
Itemized SG\&A Expenses and
Other Income/Expenses (First 2 Quarters Results) ..... 4P
Capital Expenditures and Depreciation ..... 5 P(First 2 Quarters Results and full-year plan)Major Change on Balance Sheets6 Pand Statements of Cash Flows (First 2 Quarters Results)
Non-Consolidated Basis
Statements of Income (First 2 Quarters Results) ..... 7 P
Statements of Income (Full-year plan) ..... 8P
First 2 Quarters Results Manufacturing Costs ..... 9 P

## (Notes Concerning Forward-Looking Statements)

Projections throughout these materials are provided as a reference for investors. They are based on estimates and forecasts, and shall not be regarded as pledges or guarantees. They shall be used on the full acknowledgment that actual results may naturally differ from

Fiscal 2021 Statements of Income (First 2 Quarters Results; Consolidated)

| First Quarter | $¥$ millions, rounded down |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | June 2021 Results |  | June 2020 Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,895 | 100.0 | 8,376 | 100.0 | 519 | 106.2 |
| Cost of Sales | 5,115 | 57.5 | 4,874 | - 58.2 | 241 | 105.0 |
| Gross profit | 3,780 | 42.5 | 3,502 | 41.8 | 277 | 107.9 |
| SG\&A expenses | 2,287 | 25.7 | 2,358 | 28.2 | $\triangle 70$ | 97.0 |
| Operating income | 1,492 | 16.8 | 1,143 | 13.7 | 348 | 130.5 |
| Other income | 34 |  | 109 |  | $\triangle 74$ |  |
| Other expenses | 31 |  | 1 |  | 30 |  |
| Ordinary income | 1,495 | 16.8 | 1,251 | 14.9 | 243 | 119.5 |
| Extraordinary income | - |  |  |  | - |  |
| Extraordinary expenses | 1 |  |  |  | 1 |  |
| Income before income taxes and minority interests | 1,494 | 16.8 | 1,251 | 14.9 | 242 | 119.4 |
| Corporation tax, etc. | 412 |  | 352 |  | 59 |  |
| (Tax burden) | 27.6\% |  | 28.1\% |  |  |  |
| Minority interests | $\triangle 7$ |  | $\triangle 8$ |  | 1 |  |
| Profit attributable to owners of parent | 1,089 | 12.2 | 908 | 10.8 | 181 | 120.0 |
| EPS (total shares) | $¥ 33.34$ |  | $¥ 27.78$ |  |  |  |
| EPS (minus treasury shares) | ¥36.65 |  | ¥30.04 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 29,729,200 |  | 30,223,453 |  |  |  |

Second Quarter Results $\quad \neq$ millions, rounded down

|  | Sept. 2021 Results |  | Sept. 2020 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount $\%$ | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 9,032 | 100.0 | 9,358 | 100.0 | $\triangle 325$ | 96.5 |
| Cost of Sales | 5,228 | 57.9 | 5,499 | 58.8 | $\triangle 271$ | 95.1 |
| Gross profit | 3,803 | 42.1 | 3,858 | 41.2 | $\triangle 54$ | 98.6 |
| SG\&A expenses | 2,308 | 25.6 | 2,331 | 24.9 | $\triangle 22$ | 99.1 |
| Operating income | 1,494 | 16.6 | 1,527 | 16.3 | $\triangle 32$ | 97.9 |
| Other income | 117 |  | 29 |  | 88 |  |
| Other expenses | 40 |  | 1 |  | 38 |  |
| Ordinary income | 1,571 | 17.4 | 1,554 | 16.6 | 17 | 101.1 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  |
| Extraordinary expenses | 0 |  | 1 |  | $\triangle 1$ |  |
| Income before income taxes and minority interests | 1,571 | 17.4 | 2,581 | 27.6 | $\triangle 1,010$ | 60.9 |
| Corporation tax, etc. | 434 |  | 716 |  | $\triangle 281$ |  |
| (Tax burden) | 27.7\% |  | 27.7\% |  |  |  |
| Minority interests | 0 |  | $\triangle 2$ |  | $\triangle 5$ |  |
| Profit attributable to owners of parent | 1,144 | 12.7 | 1,868 | 20.0 | $\triangle 723$ | 61.3 |

First Half Results
$¥$ millions, rounded down


Fiscal 2021 Statements of Income (Full-year plan; Consolidated)

| First Half Results | $¥$ millions, rounded down |  |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Sept. 2021 Interim Results |  | Sept. 2020 Interim Results |  | Year-on-Year Comparison |  | Sept. 2021 <br> Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of tota\| | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 17,928 | 100.0 | 17,734 | 100.0 | 193 | 101.1 | 19,080 | 100.0 | $\triangle 1,151$ | 94.0 |
| Cost of Sales | 10,344 | 57.7 | 10,374 | 58.5 | $\triangle 30$ | 99.7 | 10,940 | 57.3 | $\triangle 595$ | 94.6 |
| Gross profit | 7,583 | 42.3 | 7,360 | 41.5 | 223 | 103.0 | 8,140 | 42.7 | $\triangle 556$ | 93.2 |
| SG\&A expenses | 4,596 | 25.6 | 4,689 | 26.4 | $\triangle 92$ | 98.0 | 4,920 | 25.8 | $\triangle 323$ | 93.4 |
| Operating income | 2,987 | 16.7 | 2,671 | 15.1 | 316 | 111.8 | 3,220 | 16.9 | $\triangle 232$ | 92.8 |
| Other income | 151 |  | 138 |  | 13 |  | 90 |  | 61 |  |
| Other expenses | 72 |  | 3 |  | 68 |  | 60 |  | 12 |  |
| Ordinary income | 3,067 | 17.1 | 2,806 | 15.8 | 261 | 109.3 | 3,250 | 17.0 | $\triangle 182$ | 94.4 |
| Extraordinary income |  |  | 1,028 |  | $\triangle 1,028$ |  | - |  |  |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  | - |  | 1 |  |
| Income before income taxes and minority interests | 3,065 | 17.1 | 3,833 | 21.6 | $\triangle 767$ | 80.0 | 3,250 | 17.0 | $\triangle 184$ | 94.3 |
| Corporation tax, etc. | 846 |  | 1,068 |  | $\triangle 221$ |  | 920 |  | $\triangle 73$ |  |
| (Tax burden) | 27.6\% |  | 27.9\% |  |  |  | 28.3\% |  |  |  |
| Minority interests | $\triangle 15$ |  | $\triangle 11$ |  | $\triangle 3$ |  | $\triangle 20$ |  | 4 |  |
| Profit attributable to owners of parent | 2,234 | 12.5 | 2,776 | 15.7 | $\triangle 541$ | 80.5 | 2,350 | 12.3 | $\triangle 115$ | 95.1 |
| EPS (total shares) | $¥ 68.36$ |  | $¥ 84.94$ |  |  |  | $¥ 71.90$ |  |  |  |
| EPS (minus treasury shares) | ¥75.83 |  | ¥91.84 |  |  |  | ¥79.77 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 29,461,490 |  | 30,228,126 |  |  |  | 29,461,490 |  |  |  |

Second Half $\quad$ ¥ millions, rounded down

|  | Fiscal 2021 <br> Revised Plan |  | Fiscal 2020 Results |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Initial Plan |  | Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 18,641 | 100.0 | 18,769 | 100.0 | $\triangle 127$ | 99.3 | 19,320 | 100.0 | $\triangle 678$ | 96.5 |
| Cost of Sales | 10,955 | 58.8 | 10,803 | 57.6 | 152 | 101.4 | 11,040 | 57.1 | $\triangle 84$ | 99.2 |
| Gross profit | 7,686 | 41.2 | 7,966 | 42.4 | $\triangle 280$ | 96.5 | 8,280 | 42.9 | $\triangle 593$ | 92.8 |
| SG\&A expenses | 4,883 | 26.2 | 5,005 | 26.7 | $\triangle 121$ | 97.6 | 5,150 | 26.7 | $\triangle 266$ | 94.8 |
| Operating income | 2,802 | 15.0 | 2,960 | 15.8 | $\triangle 158$ | 94.6 | 3,130 | 16.2 | $\triangle 327$ | 89.5 |
| Other income | 258 |  | 283 |  | $\triangle 25$ |  | 260 |  | $\triangle 1$ |  |
| Other expenses | 77 |  | 62 |  | 15 |  | 20 |  | 57 |  |
| Ordinary income | 2,982 | 16.0 | 3,182 | 17.0 | $\triangle 199$ | 93.7 | 3,370 | 17.4 | $\triangle 387$ | 88.5 |
| Extraordinary income |  |  | 1 |  | $\triangle 1$ |  |  |  | - |  |
| Extraordinary expenses | 8 |  | 27 |  | $\triangle 18$ |  |  |  | 8 |  |
| Income before income taxes and minority interests | 2,974 | 16.0 | 3,156 | 16.8 | $\triangle 181$ | 94.2 | 3,370 | 17.4 | $\triangle 395$ | 88.3 |
| Corporation tax, etc. | 933 |  | 991 |  | $\triangle 58$ |  | 1,020 |  | $\triangle 86$ |  |
| (Tax burden) | 31.4\% |  | 31.4\% |  |  |  | 30.3\% |  |  |  |
| Minority interests | $\triangle 24$ |  | $\triangle 18$ |  | $\triangle 5$ |  | $\triangle 20$ |  | $\triangle 4$ |  |
| Profit attributable to owners of parent | 2,065 | 11.1 | 2,183 | 11.6 | $\triangle 117$ | 94.6 | 2,370 | 12.3 | $\triangle 304$ | 87.2 |

Full-year

|  | Fiscal 2021 <br> Revised Plan |  | $\begin{aligned} & \hline \text { Fiscal } 2020 \\ & \text { Results } \end{aligned}$ |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Initial Plan |  | Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 36,570 | 100.0 | 36,504 | 100.0 | 65 | 100.2 | 38,400 | 100.0 | $\triangle 1,830$ | 95.2 |
| Cost of Sales | 21,300 | 58.2 | 21,177 | 58.0 | 122 | 100.6 | 21,980 | 57.2 | $\triangle 680$ | 96.9 |
| Gross profit | 15,270 | 41.8 | 15,326 | 42.0 | $\triangle 56$ | 99.6 | 16,420 | 42.8 | $\triangle 1,150$ | 93.0 |
| SG\&A expenses | 9,480 | 25.9 | 9,694 | 26.6 | $\triangle 214$ | 97.8 | 10,070 | 26.2 | $\triangle 590$ | 94.1 |
| Operating income | 5,790 | 15.8 | 5,632 | 15.4 | 157 | 102.8 | 6,350 | 16.5 | $\triangle 560$ | 91.2 |
| Other income | 410 |  | 421 |  | $\triangle 11$ |  | 350 |  | 60 |  |
| Other expenses | 150 |  | 65 |  | 84 |  | 80 |  | 70 |  |
| Ordinary income | 6,050 | 16.5 | 5,988 | 16.4 | 61 | 101.0 | 6,620 | 17.2 | $\triangle 570$ | 91.4 |
| Extraordinary income | - |  | 1,030 |  | $\triangle 1,030$ |  | - |  | - |  |
| Extraordinary expenses | 10 |  | 28 |  | $\triangle 18$ |  | - |  | 10 |  |
| Income before income taxes and minority interests | 6,040 | 16.5 | 6,989 | 19.1 | $\triangle 949$ | 86.4 | 6,620 | 17.2 | $\triangle 580$ | 91.2 |
| Corporation tax, etc. | 1,780 |  | 2,060 |  | $\triangle 280$ |  | 1,940 |  | $\triangle 160$ |  |
| (Tax burden) | 29.5\% |  | 29.5\% |  |  |  | 29.3\% |  |  |  |
| Minority interests | $\triangle 40$ |  | $\triangle 30$ |  | $\triangle 9$ |  | $\triangle 40$ |  | - |  |
| Profit attributable to owners of parent | 4,300 | 11.8 | 4,959 | 13.6 | $\triangle 659$ | 86.7 | 4,720 | 12.3 | $\triangle 420$ | 91.1 |
| EPS (total shares) | $¥ 131.57$ |  | $¥ 151.73$ |  |  |  | $¥ 144.42$ |  |  |  |
| EPS (minus treasury shares) | $¥ 148.43$ |  | $¥ 164.03$ |  |  |  | $¥ 162.93$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 28,969,170 |  | 30,231,715 |  |  |  | 28,969,170 |  |  |  |

Fiscal 2021 Sales by Product Grouping
(First 2 Quarters Results and full-year revised plan; Consolidated)

| First Half |  |  |  |  |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Sept. 2021 InterimResults |  | Sept. 2020 Interim Results |  | Year-on-Year Comparison |  | Sept. 2021 <br> Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 1,625 | 9.1 | 1,639 | 9.2 | $\triangle 13$ | 99.2 | 1,662 | 8.7 | $\triangle 36$ | 97.8 |
| Surgical products | 15,851 | 88.4 | 15,646 | 88.2 | 204 | 101.3 | 16,970 | 88.9 | $\triangle 1,118$ | 93.4 |
| Treatment products | 87 | 0.5 | 111 | 0.6 | $\triangle 23$ | 78.7 | 95 | 0.5 | $\triangle 8$ | 91.5 |
| Others | 363 | 2.0 | 337 | 1.9 | 26 | 107.7 | 351 | 1.8 | 11 | 103.3 |
| Total | 17,928 | 100.0 | 17,734 | 100.0 | 193 | 101.1 | 19,080 | 100.0 | $\triangle 1,151$ | 94.0 |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 4,084 | 22.8 | 4,495 | 25.3 | $\triangle 410$ | 90.9 | 4,460 | 23.4 | $\triangle 375$ | 91.6 |
| Other non-woven products | 754 | 4.2 | 882 | 5.0 | $\triangle 127$ | 85.6 | 730 | 3.8 | 24 | 103.4 |
| Kit products | 10,924 | 60.9 | 10,193 | 57.5 | 730 | 107.2 | 11,660 | 61.1 | $\triangle 735$ | 93.7 |
| New products | 88 | 0.5 | 75 | 0.4 | 12 | 117.1 | 120 | 0.6 | $\triangle 31$ | 73.5 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 311 |  | 249 |  | 61 |  | 320 |  | $\triangle 8$ |  |
| Other non-woven products | - |  | 27 |  | $\triangle 27$ |  | - |  | - |  |
| Kit products | 1 |  | 0 |  | 0 |  | - |  | 1 |  |
| Others | 41 |  | 36 |  | 5 |  | 40 |  | 1 |  |


| Second Half |  |  |  |  |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Fiscal 2021 <br> Revised Plan |  | $\begin{gathered} \hline \text { Fiscal } 2020 \\ \text { Results } \end{gathered}$ |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 1,714 | 9.2 | 1,627 | 8.7 | 86 | 105.3 | 1,589 | 8.2 | 124 | 107.8 |
| Surgical products | 16,438 | 88.2 | 16,694 | 88.9 | $\triangle 255$ | 98.5 | 17,300 | 89.5 | $\triangle 861$ | 95.0 |
| Treatment products | 92 | 0.5 | 104 | 0.6 | $\triangle 11$ | 88.5 | 89 | 0.5 | 2 | 103.2 |
| Others | 396 | 2.1 | 344 | 1.8 | 52 | 115.4 | 341 | 1.8 | 55 | 116.4 |
| Total | 18,641 | 100.0 | 18,769 | 100.0 | $\triangle 127$ | 99.3 | 19,320 | 100.0 | $\triangle 678$ | 96.5 |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 4,065 | 21.8 | 4,787 | 25.5 | $\triangle 722$ | 84.9 | 4,410 | 22.8 | $\triangle 344$ | 92.2 |
| Other non-woven products | 705 | 3.8 | 797 | 4.3 | $\triangle 92$ | 88.4 | 690 | 3.6 | 15 | 102.2 |
| Kit products | 11,605 | 62.3 | 10,993 | 58.6 | 612 | 105.6 | 12,080 | 62.5 | $\triangle 474$ | 96.1 |
| New products | 61 | 0.3 | 114 | 0.6 | $\triangle 52$ | 53.9 | 120 | 0.6 | $\triangle 58$ | 51.5 |

Itemized external sales by subsidiary
Non-woven products
Other non-woven products
358

| 363 | $\triangle 4$ | 320 | 38 |
| ---: | ---: | ---: | ---: |
| 11 | $\triangle 11$ | - | - |
| $\triangle 0$ | $\triangle 1$ | - | $\triangle 1$ |
| 25 | 12 | 40 | $\triangle 1$ |


| Full-year |  |  |  |  |  |  |  |  | $¥$ millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Fiscal 2021 <br> Revised Plan |  | $\begin{gathered} \hline \text { Fiscal } 2020 \\ \text { Results } \end{gathered}$ |  | Year-on-Year Comparison |  | Fiscal 2021 <br> Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Sterilization products | 3,340 | 9.1 | 3,266 | 8.9 | 73 | 102.2 | 3,252 | 8.5 | 87 | 102.7 |
| Surgical products | 32,290 | 88.3 | 32,340 | 88.6 | $\triangle 50$ | 99.8 | 34,270 | 89.2 | $\triangle 1,980$ | 94.2 |
| Treatment products | 180 | 0.5 | 215 | 0.6 | $\triangle 35$ | 83.5 | 185 | 0.5 | $\triangle 5$ | 97.1 |
| Others | 760 | 2.1 | 681 | 1.9 | 78 | 111.6 | 692 | 1.8 | 67 | 109.7 |
| Total | 36,570 | 100.0 | 36,504 | 100.0 | 65 | 100.2 | 38,400 | 100.0 | $\triangle 1,830$ | 95.2 |
| Itemized surgical products |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 8,150 | 22.3 | 9,283 | 25.4 | $\triangle 1,133$ | 87.8 | 8,870 | 23.1 | $\triangle 720$ | 91.9 |
| Other non-woven products | 1,460 | 4.0 | 1,680 | 4.6 | $\triangle 220$ | 86.9 | 1,420 | 3.7 | 40 | 102.8 |
| Kit products | 22,530 | 61.6 | 21,187 | 58.0 | 1,342 | 106.3 | 23,740 | 61.8 | $\triangle 1,210$ | 94.9 |
| New products | 150 | 0.4 | 190 | 0.5 | $\triangle 40$ | 78.9 | 240 | 0.6 | $\triangle 90$ | 62.5 |
| Itemized external sales by subsidiary |  |  |  |  |  |  |  |  |  |  |
| Non-woven products | 670 |  | 612 |  | 57 |  | 640 |  | 30 |  |
| Other non-woven products | - |  | 38 |  | $\triangle 38$ |  | - |  | - |  |
| Kit products | - |  | 0 |  | $\triangle 0$ |  | - |  | - |  |
| Others | 80 |  | 62 |  | 17 |  | 80 |  | - |  |

Sales Composition by Kit Treatiment Category



Fiscal 2021 Itemized SG\&A Expenses and Other Income/Expenses

SG\&A Expenses
$\not \approx$ millions, rounded down

|  | Sept. 2021 Interim Results | Sept. 2020 Interim Results | Year-on-Year Comparison | Sept. 2021 <br> Initial Plan | Plan <br> Comparison |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Packaging and transportation | 521 | 532 | $\triangle 10$ | 546 | $\triangle 24$ |
| Losses on doubtful accounts | - | - | - |  |  |
| Samples | 160 | 176 | $\triangle 16$ | 207 | $\triangle 47$ |
| Advertising | 26 | 12 | 14 | 28 | $\triangle 1$ |
| Personnel | 2,016 | 2,064 | $\triangle 47$ | 2,147 | $\triangle 130$ |
| Travel | 210 | 186 | 24 | 256 | $\triangle 45$ |
| Communication | 72 | 66 | 6 | 75 | $\triangle 3$ |
| Consumables | 29 | 41 | $\triangle 11$ | 38 | $\triangle 8$ |
| Taxes and public charges | 176 | 162 | 14 | 171 | 5 |
| Depreciation | 404 | 438 | $\triangle 33$ | 425 | $\triangle 20$ |
| Testing and research | 228 | 255 | $\triangle 26$ | 249 | $\triangle 20$ |
| Land and housing rent | 221 | 221 | 0 | 221 | 0 |
| Miscellaneous | 227 | 248 | $\triangle 21$ | 197 | 29 |
| Others | 297 | 283 | 14 | 354 | $\triangle 56$ |
| Total | 4,596 | 4,689 | $\triangle 92$ | 4,920 | $\triangle 323$ |

Other Income/Expenses
$¥$ millions, rounded down

|  | Sept. 2021 Interim Results | Sept. 2020 Interim Results | Year-on-Year Comparison | Sept. 2021 <br> Initial Plan | Plan <br> Comparison |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Interest received | 19 | 38 | $\triangle 19$ | 29 | $\triangle 9$ |
| Interest on negotiable securities | - | - | - | - |  |
| Dividend received | 31 | 41 | $\triangle 10$ | 26 | 4 |
| (Total financial earnings) | 50 | 79 | $\triangle 29$ | 55 | $\triangle 5$ |
| Foreign exchange gain | - | 24 | $\triangle 24$ | - |  |
| Miscellaneous income | 101 | 34 | 67 | 34 | 67 |
| Total Other income | 151 | 138 | 13 | 90 | 61 |
| Paid interest | 1 | 0 | 0 | 4 | $\triangle 3$ |
| (Total financial expenses) | 1 | 0 | 0 | 4 | $\triangle 3$ |
| Foreign exchange loss | 8 | - | 8 | - | 8 |
| Miscellaneous losses | 62 | 3 | 67 | 55 | 15 |
| Total non-operating expenses | 72 | 3 | 68 | 60 | 12 |

Fiscal 2021 Capital Expenditures and Depreciation
(First 2 Quarters Results and full-year plan; Consolidated)


## Balance Sheets (Major Changes)/Statements of Cash Flows (Consolidated)

Major Changes on Balance Sheets
$\neq$ millions, rounded down

|  | Balance at Sept. 30, 2021 | Change |  | Balance at Sept. 30, 2021 | Change |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Current assets | 39,748 | $\triangle 1,573$ | Current liabilities | 8,779 | 1,189 |
| Cash and bank deposits | 18,732 | $\triangle 1,816$ | Notes and accounts payable | 4,673 | 58 |
| Notes and accounts receivable | 11,400 | 9 | Accrued expenses | 372 | 8 |
| Short-term investments | - | - | Long-term loans due within 1 year | - | -64 |
| Inventories | 9,094 | 289 | Income taxes | 920 | $\triangle 187$ |
| Others | 520 | $\triangle 55$ | Allowance for employees' bonuses | 464 | $\triangle 56$ |
|  |  |  | Payable notes for equipment | 1,905 | 1,639 |
|  |  |  | Reserve for disaster loss | - | - |
|  |  |  | Others | 442 | $\triangle 209$ |
| Fixed assets | 64,873 | 551 | Long-term liabilities | 2,143 | 40 |
| Property, plant and equipment | 53,257 | 462 | Long-term borrowings | - | - |
| Buildings and structures | 21,879 | $\triangle 453$ | Others | 2,143 | 40 |
| Machinery, equipment and vehicles | 6,771 | $\triangle 395$ | Total liabilities | 10,922 | 1,229 |
| Land | 9,608 | 27 | Total net assets | 93,699 | $\triangle 2,252$ |
| Construction in progress | 14,120 | 1,423 | Common stock | 7,123 | - |
| Others | 876 | $\triangle 138$ | Capital surplus | 8,336 | - |
| Intangibles | 1,755 | $\triangle 195$ | Retained earnings | 87,369 | 1,220 |
| Investments and others | 9,860 | 284 | Treasury stock | $\triangle 12,804$ | $\triangle 3,901$ |
| Investments securities | 8,369 | 381 | Others | 3,673 | 428 |
| Others | 1,490 | $\triangle 97$ |  |  |  |
| Total assets | 104,621 | $\triangle 1,022$ | Total liabilities and shareholders' equity | 104,621 | $\triangle 1,022$ |

* Comparison with end of previous fiscal year:

Equity ratio increased from $90.8 \%$ at the end of the previous fiscal year to $89.5 \%$.

Statements of Cash Flows
$¥$ millions, rounded down

| I Operating activities | 3,926 | Income before income taxes Depreciation Incomes taxes paid | $\begin{array}{r} 3,065 \\ 2,038 \\ \triangle 1,059 \end{array}$ |
| :---: | :---: | :---: | :---: |
| II Investing activities | $\triangle 897$ | purchase of tangible fixed assets Purchase of intangible fixed assets | $\begin{array}{r} \triangle 682 \\ \triangle 82 \end{array}$ |
| III Financing activities | $\triangle 4,974$ | Cash dividends paid | $\triangle 1,011$ |
| IV Effect of exchange rate changes | 155 |  |  |
| Net changes in cash and cash equivalents | $\triangle 1,789$ |  |  |

Fiscal 2021 Statements of Income (First 2 Quarters Results; Non-consolidated)

First Quarter $\quad \neq$ millions, rounded down

|  | June 2021 Results |  | June 2020 Results |  | Year-on-Year Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,713 | 100.0 | 8,292 | 100.0 | 420 | 105.1 |
| Cost of Sales | 5,109 | 58.6 | 4,965 | 59.9 | 144 | 102.9 |
| Gross profit | 3,603 | 41.4 | 3,327 | 40.1 | 276 | 108.3 |
| SG\&A expenses | 2,229 | 25.6 | 2,300 | 27.7 | $\triangle 71$ | 96.9 |
| Operating income | 1,374 | 15.8 | 1,026 | 12.4 | 347 | 133.9 |
| Other income | 27 |  | 51 |  | $\triangle 23$ |  |
| Other expenses | 44 |  | 7 |  | 37 |  |
| Ordinary income | 1,357 | 15.6 | 1,071 | 12.9 | 286 | 126.7 |
| Extraordinary income | - |  | - |  | - |  |
| Extraordinary expenses | 1 |  | - |  | 1 |  |
| Income before income taxes | 1,356 | 15.6 | 1,071 | 12.9 | 285 | 126.6 |
| Corporation tax, etc. | 385 |  | 307 |  | 77 |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  |
| Net income | 971 | 11.2 | 764 | 9.2 | 207 | 127.2 |
| EPS (total shares) | $¥ 29.73$ |  | $¥ 23.38$ |  |  |  |
| EPS (minus treasury shares) | $¥ 32.68$ |  | $¥ 25.28$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 29,729,200 |  | 30,223,453 |  |  |  |


| Second Quarter |  |  | $¥$ millions, rounded down |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Sept. 2021 Results |  | Sept. 2020 Results |  | Year-on-Year Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% |
| Net sales | 8,864 | 100.0 | 9,150 | 100.0 | $\triangle 285$ | 96.9 |
| Cost of Sales | 5,222 | 58.9 | 5,513 | 60.3 | $\triangle 291$ | 94.7 |
| Gross profit | 3,642 | 41.1 | 3,636 | 39.7 | 6 | 100.2 |
| SG\&A expenses | 2,254 | 25.4 | 2,281 | 24.9 | $\triangle 27$ | 98.8 |
| Operating income | 1,388 | 15.7 | 1,354 | 14.8 | 33 | 102.5 |
| Other income | 112 |  | 40 |  | 71 |  |
| Other expenses | 39 |  | 7 |  | 32 |  |
| Ordinary income | 1,461 | 16.5 | 1,387 | 15.2 | 73 | 105.3 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  |
| Extraordinary expenses | 0 |  | 1 |  | $\triangle 1$ |  |
| Income before income taxes | 1,460 | 16.5 | 2,415 | 26.4 | $\triangle 954$ | 60.5 |
| Corporation tax, etc. | 414 |  | 692 |  | $\triangle 278$ |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  |
| Net income | 1,046 | 11.8 | 1,722 | 18.8 | $\triangle 676$ | 60.7 |

First Half

|  | Sept. 2021 Interim Results |  | Sept. 2020 Interim Results |  | Year-on-Year Comparison |  | Sept. 2021 <br> Initial Plan |  | Plan Comparison |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 17,577 | 100.0 | 17,442 | 100.0 | 135 | 100.8 | 18,720 | 100.0 | $\triangle 1,142$ | 93.9 |
| Cost of Sales | 10,331 | 58.8 | 10,479 | 60.1 | $\triangle 147$ | 98.6 | 11,010 | 58.8 | $\triangle 678$ | 93.8 |
| Gross profit | 7,246 | 41.2 | 6,963 | 39.9 | 282 | 104.1 | 7,710 | 41.2 | $\triangle 463$ | 94.0 |
| SG\&A expenses | 4,483 | 25.5 | 4,581 | 26.3 | $\triangle 98$ | 97.9 | 4,770 | 25.5 | $\triangle 286$ | 94.0 |
| Operating income | 2,762 | 15.7 | 2,381 | 13.7 | 380 | 116.0 | 2,940 | 15.7 | $\triangle 177$ | 94.0 |
| Other income | 140 |  | 92 |  | 47 |  | 50 |  | 90 |  |
| Other expenses | 83 |  | 14 |  | 69 |  | 70 |  | 13 |  |
| Ordinary income | 2,819 | 16.0 | 2,459 | 14.1 | 359 | 114.6 | 2,920 | 15.6 | $\triangle 100$ | 96.5 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  | - |  | - |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  | - |  | 1 |  |
| Income before income taxes | 2,817 | 16.0 | 3,486 | 20.0 | $\triangle 669$ | 80.8 | 2,920 | 15.6 | $\triangle 102$ | 96.5 |
| Corporation tax, etc. | 799 |  | 1,000 |  | $\triangle 200$ |  | 830 |  | $\triangle 30$ |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  | 28.4\% |  |  |  |
| Net income | 2,017 | 11.5 | 2,486 | 14.3 | $\triangle 468$ | 81.1 | 2,090 | 11.2 | $\triangle 72$ | 96.5 |
| EPS (total shares) | $\ddagger 61.73$ |  | ¥76.08 |  |  |  | $¥ 63.95$ |  |  |  |
| EPS (minus treasury shares) | $¥ 68.48$ |  | $¥ 82.25$ |  |  |  | $¥ 70.94$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 29,461,490 |  | 30,228,126 |  |  |  | 29,461,490 |  |  |  |

Fiscal 2021 Statements of Income (First 2 Quarters Results; Non-consolidated)

| First Half |  |  |  |  |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Sept. 2021 Interim Results |  | Sept. 2020 Interim Results |  | Year-on-Year Comparison |  | Sept. 2021 <br> Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 17,577 | 100.0 | 17,442 | 100.0 | 135 | 100.8 | 18,720 | 100.0 | $\triangle 1,142$ | 93.9 |
| Cost of Sales | 10,331 | 58.8 | 10,479 | 60.1 | $\triangle 147$ | 98.6 | 11,010 | 58.8 | $\triangle 678$ | 93.8 |
| Gross profit | 7,246 | 41.2 | 6,963 | 39.9 | 282 | 104.1 | 7,710 | 41.2 | $\triangle 463$ | 94.0 |
| SG\&A expenses | 4,483 | 25.5 | 4,581 | 26.3 | $\triangle 98$ | 97.9 | 4,770 | 25.5 | $\triangle 286$ | 94.0 |
| Operating income | 2,762 | 15.7 | 2,381 | 13.7 | 380 | 116.0 | 2,940 | 15.7 | $\triangle 177$ | 94.0 |
| Other income | 140 |  | 92 |  | 47 |  | 50 |  | 90 |  |
| Other expenses | 83 |  | 14 |  | 69 |  | 70 |  | 13 |  |
| Ordinary income | 2,819 | 16.0 | 2,459 | 14.1 | 359 | 114.6 | 2,920 | 15.6 | $\triangle 100$ | 96.5 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  | - |  | - |  |
| Extraordinary expenses | 1 |  | 1 |  | $\triangle 0$ |  | - |  | 1 |  |
| Income before income taxes | 2,817 | 16.0 | 3,486 | 20.0 | $\triangle 669$ | 80.8 | 2,920 | 15.6 | $\triangle 102$ | 96.5 |
| Corporation tax, etc. | 799 |  | 1,000 |  | $\triangle 200$ |  | 830 |  | $\triangle 30$ |  |
| (Tax burden) | 28.4\% |  | 28.7\% |  |  |  | 28.4\% |  |  |  |
| Net income | 2,017 | 11.5 | 2,486 | 14.3 | $\triangle 468$ | 81.1 | 2,090 | 11.2 | $\triangle 72$ | 96.5 |
| EPS (total shares) | $¥ 61.73$ |  | $¥ 76.08$ |  |  |  | $¥ 63.95$ |  |  |  |
| EPS (minus treasury shares) | $¥ 68.48$ |  | $¥ 82.25$ |  |  |  | ¥70.94 |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 29,461,490 |  | 30,228,126 |  |  |  | 29,461,490 |  |  |  |


| Second Half |
| :--- |
| \begin{tabular}{\|l|r|r|r|r|r|r|r|r|r|}
\hline
\end{tabular} |


| Full-year |  |  |  |  |  |  |  |  | millions, rounded down |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Fiscal 2021 <br> Revised Plan |  | $\begin{gathered} \text { Fiscal } 2020 \\ \text { Results } \end{gathered}$ |  | Year-on-Year Comparison |  | Fiscal 2021 Initial Plan |  | Plan Comparison |  |
|  | Amount | \% of total | Amount | \% of total | Amount | \% | Amount | \% of total | Amount | \% |
| Net sales | 35,820 | 100.0 | 35,813 | 100.0 | 6 | 100.0 | 37,680 | 100.0 | $\triangle 1,860$ | 95.1 |
| Cost of Sales | 21,180 | 59.1 | 21,313 | 59.5 | $\triangle 133$ | 99.4 | 22,140 | 58.8 | $\triangle 960$ | 95.7 |
| Gross profit | 14,640 | 40.9 | 14,499 | 40.5 | 140 | 101.0 | 15,540 | 41.2 | $\triangle 900$ | 94.2 |
| SG\&A expenses | 9,210 | 25.7 | 9,455 | 26.4 | $\triangle 245$ | 97.4 | 9,750 | 25.9 | $\triangle 540$ | 94.5 |
| Operating income | 5,430 | 15.2 | 5,043 | 14.1 | 386 | 107.7 | 5,790 | 15.4 | $\triangle 360$ | 93.8 |
| Other income | 600 |  | 566 |  | 33 |  | 510 |  | 90 |  |
| Other expenses | 170 |  | 87 |  | 82 |  | 100 |  | 70 |  |
| Ordinary income | 5,860 | 16.4 | 5,522 | 15.4 | 337 | 106.1 | 6,200 | 16.5 | $\triangle 340$ | 94.5 |
| Extraordinary income | - |  | 1,028 |  | $\triangle 1,028$ |  | - |  | - |  |
| Extraordinary expenses | 10 |  | 28 |  | $\triangle 18$ |  | - |  | 10 |  |
| Income before income taxes | 5,850 | 16.3 | 6,522 | 18.2 | $\triangle 672$ | 89.7 | 6,200 | 16.5 | $\triangle 350$ | 94.4 |
| Corporation tax, etc. | 1,660 |  | 1,853 |  | $\triangle 193$ |  | 1,760 |  | $\triangle 100$ |  |
| (Tax burden) | 28.4\% |  | 28.4\% |  |  |  | 28.4\% |  |  |  |
| Net income | 4,190 | 11.7 | 4,669 | 13.0 | $\triangle 479$ | 89.7 | 4,440 | 11.8 | $\triangle 250$ | 94.4 |
| EPS (total shares) | $¥ 128.20$ |  | $¥ 142.87$ |  |  |  | $¥ 135.85$ |  |  |  |
| EPS (minus treasury shares) | $¥ 144.64$ |  | $¥ 154.45$ |  |  |  | $¥ 153.27$ |  |  |  |
| Number of shares outstanding | 32,682,310 |  | 32,682,310 |  |  |  | 32,682,310 |  |  |  |
| Weighted-average number of shares outstanding (after deducting treasury shares) | 28,969,170 |  | 30,231,715 |  |  |  | 28,969,170 |  |  |  |

First 2 Quarters Results Manufacturing Costs (Non-consolidated)

Manufacturing Costs
$¥$ millions, rounded down

|  | $\mathbf{2 0 1 2 . 9}$ | $\mathbf{2 0 1 3 . 9}$ | $\mathbf{2 0 1 4 . 9}$ | $\mathbf{2 0 1 5 . 9}$ | $\mathbf{2 0 1 6 . 9}$ | $\mathbf{2 0 1 7 . 9}$ | $\mathbf{2 0 1 8 . 9}$ | $\mathbf{2 0 1 9 . 9}$ | $\mathbf{2 0 2 0 . 9}$ | $\mathbf{2 0 2 1 . 9}$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Materials | 5,009 | 5,323 | 5,692 | 5,964 | 6,382 | 6,266 | 6,387 | 6,391 | 6,330 | 6,241 |
| Personnel | 906 | 949 | 949 | 886 | 884 | 877 | 860 | 819 | 906 | 876 |
| Outsourcing | 208 | 209 | 210 | 188 | 205 | 199 | 208 | 167 | 226 | 199 |
| Others | 1,601 | 1,503 | 1,402 | 1,494 | 2,173 | 3,392 | 3,285 | 3,055 | 2,767 | 2,594 |
| Total | 7,726 | 7,985 | 8,254 | 8,533 | 9,645 | 10,735 | 10,741 | 10,434 | 10,231 | 9,912 |


| Change |
| :--- |


|  | $\mathbf{2 0 1 2 . 9}$ | $\mathbf{2 0 1 3 . 9}$ | $\mathbf{2 0 1 4 . 9}$ | $\mathbf{2 0 1 5 . 9}$ | $\mathbf{2 0 1 6 . 9}$ | $\mathbf{2 0 1 7 . 9}$ | $\mathbf{2 0 1 8 . 9}$ | $\mathbf{2 0 1 9 . 9}$ | $\mathbf{2 0 2 0 . 9}$ | $\mathbf{2 0 2 1 . 9}$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Materials | 2.7 | 6.3 | 6.9 | 4.8 | 7.0 | $\triangle 1.8$ | 1.9 | 0.1 | $\triangle 1.0$ | $\triangle 1.4$ |
| Personnel | 1.6 | 4.8 | $\triangle 0.1$ | $\triangle 6.6$ | $\triangle 0.3$ | $\triangle 0.8$ | $\triangle 1.9$ | $\triangle 4.7$ | 10.6 | $\triangle 3.2$ |
| Outsourcing | 19.7 | 0.8 | 0.5 | $\triangle 10.8$ | 9.4 | $\triangle 3.2$ | 5.0 | $\triangle 20.1$ | 35.5 | $\triangle 11.8$ |
| Others | $\triangle 6.5$ | $\triangle 6.2$ | $\triangle 6.7$ | 6.6 | 45.5 | 56.1 | $\triangle 3.2$ | $\triangle 7.0$ | $\triangle 9.4$ | $\triangle 6.3$ |
| Total | 0.9 | 3.4 | 3.4 | 3.4 | 13.0 | 11.3 | 0.1 | $\triangle 2.9$ | $\triangle 1.9$ | $\triangle 3.1$ |

\% of total (\%)

|  | $\mathbf{2 0 1 2 . 9}$ | $\mathbf{2 0 1 3 . 9}$ | $\mathbf{2 0 1 4 . 9}$ | $\mathbf{2 0 1 5 . 9}$ | $\mathbf{2 0 1 6 . 9}$ | $\mathbf{2 0 1 7 . 9}$ | $\mathbf{2 0 1 8 . 9}$ | $\mathbf{2 0 1 9 . 9}$ | $\mathbf{2 0 2 0 . 9}$ | $\mathbf{2 0 2 1 . 9}$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Materials | 64.8 | 66.7 | 69.0 | 69.9 | 66.2 | 58.4 | 59.5 | 61.3 | 61.9 | 63.0 |
| Personnel | 11.7 | 11.9 | 11.5 | 10.4 | 9.2 | 8.2 | 8.0 | 7.9 | 8.9 | 8.8 |
| Outsourcing | 2.7 | 2.6 | 2.6 | 2.2 | 2.1 | 1.9 | 1.9 | 1.6 | 2.2 | 2.0 |
| Others | 20.7 | 18.8 | 17.0 | 17.5 | 22.5 | 31.6 | 30.6 | 29.3 | 27.1 | 26.2 |
| Total | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 | 100.0 |


| Materials and <br> outsourcing | 67.5 | 69.3 | 71.5 | 72.1 | 68.3 | 60.2 | 61.4 | 62.9 | 64.1 | 65.0 |
| :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- |




